Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-Exposure Prophylaxis Outcome of Zamerovimab and Mazorelvimab Injection and Rabies Vaccine in Grade III Rabies Exposure Cases From Single-Dog Multiple-Bite Incidents: A Real-World Prospective Study

NCT07624461 is registered in ClinicalTrials.gov with Synermore Biologics (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT07624461
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07624461 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-Exposure Prophylaxis Outcome of Zamerovimab and Mazorelvimab Injection and Rabies Vaccine in Grade III Rabies Exposure Cases From Single-Dog Multiple-Bite Incidents: A Real-World Prospective Study
Lead sponsor
Synermore Biologics (Suzhou) Co., Ltd.
Phase
Observational
Overall status
Active, not recruiting
Start date
June 6, 2025
Completion date
December 31, 2026
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rabies, rabies post-exposure prophylaxis